The predictive value of ERICA in breast cancer recurrence. A univariate and multivariate analysis
- PMID: 7508116
The predictive value of ERICA in breast cancer recurrence. A univariate and multivariate analysis
Abstract
In breast cancer, primary tumor size (T), the number of lymph node metastases (#N), the biochemical estrogen (ER), and progesterone (PGR) receptor status have all been important prognostic variables. We evaluated the significance of the immunocytochemical measurement of estrogen receptors suing the ERICA method. To determine the relative prognostic value of these variables T, #N, ER, PGR, ERICA and adjuvant treatment, (ADJ), univariate and multivariate analyses of disease-free survival (DFS) were performed for 154 primary breast cancer patients who were diagnosed in 1985 to 1986 at Women's College Hospital and followed prospectively. We analyzed ERICA results using different classification systems, and assessed clinical cut points for the univariate and multivariate context. The variables consistently included in the best Cox stepwise regression are T, (p < 0.01), ADJ (p < 0.01), #N (p < 0.01), and ERICA (p < 0.01). There was weaker evidence of an association between DFS and the biochemically determined ER; ER was not included in the model with a cut point at 10 fmol mg of protein. This illustrates the value of the ERICA method in predicting outcome, and suggests the need to consider ERICA values for clinical decision making.
Similar articles
-
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31. Breast Cancer Res Treat. 2009. PMID: 18668363 Clinical Trial.
-
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.J Clin Oncol. 2007 Sep 1;25(25):3846-52. doi: 10.1200/JCO.2007.11.9453. Epub 2007 Aug 6. J Clin Oncol. 2007. PMID: 17679725 Clinical Trial.
-
Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival.Gynecol Oncol. 1996 Oct;63(1):28-33. doi: 10.1006/gyno.1996.0273. Gynecol Oncol. 1996. PMID: 8898164
-
A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.Eur J Surg Oncol. 2013 Oct;39(10):1046-52. doi: 10.1016/j.ejso.2013.06.024. Epub 2013 Jul 26. Eur J Surg Oncol. 2013. PMID: 23890870
-
[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 21029696 Chinese.
Cited by
-
Factors associated with local breast cancer recurrence after lumpectomy alone.Ann Surg Oncol. 1996 Jul;3(4):358-66. doi: 10.1007/BF02305665. Ann Surg Oncol. 1996. PMID: 8790848
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials